BTIG initiated coverage of Absci with a Buy rating and $9 price target. The firm projects $2.2B in peak sales for lead internal candidate ABS-201 across androgenetic alopecia and endometriosis, adding that ABS-201 is "potentially the GLP-1 moment for hair loss." Absci's AI platform is "a genuine technological moat," the analyst added.
